Fremont, CA (PRWEB) February 28, 2012
Optovue Inc., reports that for fiscal year 2011, unit sales of the flagship RTVue® FD-OCT and innovative iVue® Compact SD-OCT are up 32% over the 2010 unit sales level. The company also noted that the December 2011 U.S. sales were yet again at record numbers, surpassing the 2010 December U.S. sales orders.
“Gaining market share in the home country where Optovue manufactures is always satisfying,” stated John Hawley, VP of Domestic Sales. “The mission in 2012 is to continue our market growth world-wide, utilizing our new TCP (Total Cornea Power) and VTRAC (Eye Tracking) options, as well as expand our iWellness programs.”
About RTVue®, iVue® and iStand™
RTVue was the first FDA cleared Spectral-Domain OCT launched in the United States, and also the first OCT cleared by the U.S. Food and Drug Administration for both corneal and retinal imaging. The iVue is the compact version of the RTVue OCT, offering the same scanning speed and resolution as the larger system, that includes scanning and reports for retina, retina nerve fiber and cornea assessment by the clinician. iStand is a rolling floor stand option for iVue. When mounted to iStand, patients are able to be scanned in various positions including the supine position.
About Optovue® (http://www.optovue.com)
Optovue Inc. is a privately-held ophthalmic device company dedicated to working with eye care professionals and clinical researchers to lead the commercialization of new imaging modalities that improve diagnosis and therapy of ocular disease. Optovue has achieved widespread market success through a combination of unique data analysis design, a reputation for excellent customer service, and rapid innovation of its technology in response to physician feedback. The company is headquartered in Fremont, CA, with operations in Carlsbad, CA and European operations in Dossenheim, Germany.
# # #